Supernus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT04143217
- Locations
- 🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸Gulfcoast Research Center, Fort Myers, Florida, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
- Conditions
- Spasticity
- Interventions
- Drug: Phase 2; Low Dose MYOBLOCDrug: Phase 2; PlaceboDrug: Phase 3; PlaceboDrug: Phase 2; High Dose MYOBLOCDrug: Phase 3; MYOBLOC
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT04099667
- Locations
- 🇺🇸
Nova Clinical Research, LLC, Bradenton, Florida, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Rancho Research Institute, Downey, California, United States
Therapy for Migraine Prevention in Children 6-11 Years of Age
- Conditions
- Migraine DisordersHeadache Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04050293
- Locations
- 🇺🇸
CNS Healthcare, Memphis, Tennessee, United States
Classroom Study of SPN-812 in Children With ADHD
- Conditions
- ADHD
- Interventions
- Drug: PlaceboDrug: 200 mg SPN-812
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Registration Number
- NCT04016792
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT04016779
- Locations
- 🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸Gulfcoast Research Center, Fort Myers, Florida, United States
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT03944785
- Locations
- 🇺🇸
Hartford Healthcare, Vernon, Connecticut, United States
🇺🇸Southeast Neuroscience Center, LLC, Gray, Louisiana, United States
🇺🇸NYU Winthrop Hospital, Mineola, New York, United States
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)Impulsive Aggression
- Interventions
- Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI)Diagnostic Test: Magnetic Resonance Spectroscopy (MRS)Behavioral: Point Subtraction Aggression Paradigm (PSAP) TaskDrug: Placebo
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03638466
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC., Maitland, Florida, United States
🇺🇸University of South Florida- Dept. of Psychiatry and Neurosciences, Tampa, Florida, United States
🇺🇸Meridien Research aka Florida Clinical Research Center, LLC, Lakeland, Florida, United States
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
- Conditions
- Impulsive Aggression
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03615703
- Locations
- 🇺🇸
Meridien Research, Inc., Orlando, Florida, United States
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03597503
- Locations
- 🇺🇸
iResearch Atlanta, Decatur, Georgia, United States
🇺🇸Hassmann Research Institute, Berlin, New Jersey, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
- Conditions
- Focal Impaired Awareness Seizures
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03474770
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia